SKTO SK3 Group Inc (CE)

SK3 Group (OTC-PINK: SKTO) to Manage More Than 6,000 Additional Patients on the PharmaJanes.com Delivery Ordering Platform

LOS ANGELES, CA--(Marketwired - May 27, 2014) - SK3 Group, Inc (OTC Pink: SKTO) (PINKSHEETS: SKTO) ("the Company") is pleased to announce that as part of its execution of its acquisition strategy it has signed a management agreement with a major Los Angeles medical cannabis collective operating in the high traffic area of Los Angeles off of Melrose Ave. SK3 is currently working to transition the current patients exclusively onto the PharmaJanes.com ordering platform. As a result of this agreement, the Pharmajanes.com ordering platform will see an infusion of an additional 6000 patients. 

"This is exactly the kind of acquisition that will deliver value directly to the bottom line," said Company President Artemus Mayor. "As we grow the patient base for www.pharmajanes.com and our related businesses we expect to see tremendous growth."

FDA Statement The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.

About SK3 SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.

Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SK3 Group Investor Relations investors@medicalgreens.com